Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease

被引:28
作者
Cheong, Jae Hoon
Kim, Gwang Ha [1 ,2 ]
Lee, Bong Eun
Choi, Moon Ki
Moon, Ji Yoon
Ryu, Dong Yup
Kim, Dong Uk
Song, Geun Am
机构
[1] Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan 602739, South Korea
[2] Pusan Natl Univ Hosp, Med Res Inst, Pusan 602739, South Korea
关键词
Gastroesophageal reflux disease; gastroesophageal flap valve; proton pump inhibitor; HELICOBACTER-PYLORI INFECTION; BODY-MASS INDEX; ATROPHIC GASTRITIS; DUODENAL-ULCER; SYMPTOM RELIEF; HIATAL-HERNIA; ESOPHAGITIS; OMEPRAZOLE; PREVALENCE; PH;
D O I
10.3109/00365521.2011.579154
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. Limited information is available on predictors of the response to proton pump inhibitor (PPI) treatment in patients with gastroesophageal reflux disease (GERD). Endoscopic grading of gastroesophageal flap valve (GEFV) is simple and reproducible, and can provide useful information on patients with suspected reflux undergoing an endoscopy. The aim of this study was to prospectively identify predictors, including endoscopic findings such as GEFV, for PPI treatment outcomes in patients with GERD. Material and methods. One hundred and fifty consecutive patients with GERD were enrolled. All patients were treated with pantoprazole 40 mg daily for 8 weeks. Treatment response was defined as greater than 50% reduction in symptom scores between the two symptom assessments (i.e., over 4 or 8 weeks). Univariate and multivariate logistic regression analyses between responders and non-responders were performed to identify variables predicting response to pantoprazole treatment. Results. Of the 150 consecutive patients considered for this study, 31 were excluded based on exclusion criteria and/or refusal to participate, leaving 119 eligible patients. After 4-week pantoprazole treatment, 70 of 119 (58.8%) patients were classified as responders. Patients with obesity and Helicobacter pylori infection demonstrated a higher response rate to 4-week pantoprazole treatment (odds ratio (OR) 5.28, p = 0.008; OR 3.76, p = 0.023, respectively). Patients with abnormal GEFV showed a lower response rate to 4-week treatment (OR 0.17, p = 0.016). After 8-week treatment, 86 of 119 (72.3%) patients were classified as responders. Abnormal GEFV and aspirin intake were associated with a lower response rate to 8-week treatment (OR 0.17, p = 0.021; OR 0.11, p = 0.020, respectively). Conclusions. Abnormal GEFV was a significant independent factor predicting poor response to both 4-week and 8-week pantoprazole treatment. Endoscopic grading of GEFV provides useful information for predicting the response to PPI treatment in patients with GERD.
引用
收藏
页码:789 / 796
页数:8
相关论文
共 45 条
[1]  
ADLER RH, 1958, SURGERY, V44, P63
[2]  
[Anonymous], 2000, The Asian Pacific perspective. Redefining Obesity and its Treatment
[3]   Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole [J].
Carlsson, R ;
Dent, J ;
Watts, R ;
Riley, S ;
Sheikh, R ;
Hatlebakk, J ;
Haug, K ;
de Groot, G ;
van Oudvorst, A ;
Dalvag, A ;
Junghard, O ;
Wiklund, I .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (02) :119-124
[4]   Is obesity associated with gastropharyngeal reflux disease? [J].
Choi, Cheol Woong ;
Kim, Gwang Ha ;
Song, Chul Soo ;
Wang, Soo Geun ;
Lee, Byung Joo ;
I, Hoseok ;
Kang, Dae Hwan ;
Song, Geun Am .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (02) :265-271
[5]   Rabeprazole in treatment of acid peptic diseases - Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD) [J].
Cloud, ML ;
Enas, N ;
Humphries, TJ ;
Bassion, S .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (05) :993-1000
[6]   Endoscopic esophagitis and gastroesophageal flap valve [J].
Contractor, QQ ;
Akhtar, SS ;
Contractor, TQ .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1999, 28 (03) :233-237
[7]   Effects of non-steroidal anti-inflammatory drugs (NSAIDS) on acid reflux in patients with gastroesophageal reflux disease (GERD). [J].
Cryer, B ;
Spechler, SJ .
GASTROENTEROLOGY, 2000, 118 (04) :A862-A862
[8]   Effectiveness of Proton Pump Inhibitors in Nonerosive Reflux Disease [J].
Dean, Bonnie B. ;
Gano, Anacleto D., Jr. ;
Knight, Kevin ;
Ofman, Joshua J. ;
Fass, Ronnie .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (08) :656-664
[9]   The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain [J].
Fass, R ;
Fennerty, MB ;
Ofman, JJ ;
Gralnek, IM ;
Johnson, C ;
Camargo, E ;
Sampliner, RE .
GASTROENTEROLOGY, 1998, 115 (01) :42-49
[10]   Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression [J].
Frazzoni, M ;
De Micheli, E ;
Grisendi, A ;
Savarino, V .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (05) :881-886